Hepatitis C treatment Maviret is now funded
05 Feb 2019
PHARMAC is now funding the new hepatitis C treatment,
Maviret (glecaprevir and pibrentasvir), a potential cure for people with
chronic hepatitis C infection regardless of the type or genotype.
development will increase access to new treatment for approximately 21,000
people, both diagnosed and undiagnosed. This includes many patients who haven't
previously been able to benefit from currently funded treatments.
continues to play a vital role in the treatment of hepatitis C in New Zealand.
- Maviret is a simpler treatment than what has
currently been available - just one daily dose for a minimum of eight weeks
with very high cure rates.
- There is no requirement for pre-treatment
genotype testing meaning prescribing by general practitioners and other
community based prescribers will become generally more straight forward.
- The new treatment has fewer side effects and
fewer interactions with other medicines than currently funded treatments.
- Only those pharmacies registered as a Maviret
AbbVie Care Pharmacy will be able to dispense the new treatment - a list of these pharmacies is available on the Maviret
- Less paperwork is involved - prescribers only
have to fill out a prescription for Maviret. Completing a distribution request
form is no longer required.
Education materials, including clinical pathways developed by the Ministry of Health's
Hepatitis C Implementation Advisory Group and a BPAC resource commissioned by PHARMAC, have been revised to support the use of hepatitis C treatments in primary care.
more information and copies of the updated resources visit the Ministry of Health and PHARMAC websites.
Read the Midland region hepatitis c update (January 2019).
further information please access the Chronic Hepatitis C pathway via Midland Region Community HealthPathways.